Kristie Blum, MD

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (136 ratings)

Role

Hematology Oncology
Specialty

Lymphoma
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2003

Request Appointment

Background

Kristie A. Blum, MD, is a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. A board certified hematologist, Dr. Blum has extensive experience in the clinical development of novel therapeutics for patients with aggressive B-cell non-Hodgkin's lymphoma and Hodgkin's lymphoma. Prior to joining Emory in 2017, Dr. Blum was a professor in the Division of Hematology in the Department of Internal Medicine at The Ohio State University - James Cancer Hospital and Solove Research Institute where she was also the director of the Lymphoma Clinical Research Program.

Dr. Blum received her medical degree from the University of Miami School of Medicine in Miami, Florida. She completed her residency in internal medicine at the University of Virginia in Charlottesville, Virginia. She also completed a fellowship in hematology/oncology at Washington University in St. Louis, Missouri and Vanderbilt University in Nashville, Tennessee.

Titles & Roles

Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Co-Director, Lymphoma Program

Winship Cancer Institute of Emory University

Education & Training

Education

Fellowship, Hematology & Oncology, 2003
Washington University
Fellowship, Hematology & Oncology, 2001
Vanderbilt University
Internship, Internal Medicine, 2000
University of Virginia
Medical Education, Internal Medicine, 1997
University of Miami

Board Certifications

Medical Oncology
American Board of Internal Medicine, 2004
Hematology
American Board of Internal Medicine, 2004

Professional Memberships

Dr. Blum is co-chair of the NCI Lymphoma Steering Committee. She is also a member of the Lymphoma Research Foundation Scientific Advisory Board, the Alliance Co-Operative Group Lymphoma Committee, the American Society of Hematology Clinical Research Mentoring Program, and the National Comprehensive Cancer Network Hodgkin's Lymphoma Panel. She developed and chaired the first two Lymphoma Research Foundation Clinical Research Mentoring Programs from 2013-2015.

View Current Clinical Trials


A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) Phase I Conditions NHL, NHL, Relapsed, Adult Location Emory University Hospital Midtown, Winship Cancer Institute
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Phase I/II Conditions Diffuse Large B-Cell Lymphoma Location Winship Cancer Institute
ANHL1931-ADULT Phase III Location Emory Saint Joseph's Hospital, Winship Cancer Institute
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Phase III Conditions CD20 Positive, Mantle Cell Lymphoma Location Emory Saint Joseph's Hospital, Winship Cancer Institute
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Phase II Conditions Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Location Winship Cancer Institute

Grants

View Grants

Grant Number	Title
1K12CA237806-01	Emory Clinical Oncology Career Development Award K12 Program
5K12CA237806-02	Emory Clinical Oncology Career Development Award K12 Program
5K12CA237806-03	Emory Clinical Oncology Career Development Award K12 Program

Title/Journal	Authors	Publication Date
Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma. Blood advances	SC Rutherford, J Yin, LD Pederson, KA Blum, P Martin, SH Jung, B Grant, C Rosenbaum, BD Cheson, NL Bartlett, SJ Mandrekar, JP Leonard	26/03/2024
A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma. Haematologica	TA Fehniger, MP Watkins, N Ezenwajiaku, F Wan, DD Hurd, AF Cashen, KA Blum, A Goy, TS Fenske, ND Wagner-Johnston, K Carson, MJ Siegel, D Russler-Germain, SE Schneider, N Mehta-Shah, B Kahl, NL Bartlett	01/03/2024
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era. Blood advances	SH Desai, MA Spinner, AM Evens, A Sykorova, V Bachanova, G Goyal, B Kahl, K Dorritie, J Azzi, VP Kenkre, C Chang, J Michalka, SM Ansell, B Fusco, N Sumransub, H Hatic, R Saba, U Ibrahim, EI Harris, H Shah, N Wagner-Johnston, S Arai, GS Nowakowski, H Mocikova, D Jagadeesh, KA Blum, C Diefenbach, S Iyengar, KC Rappazzo, F Baidoun, Y Choi, V Prochazka, RH Advani, I Micallef	12/12/2023
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood advances	N Epperla, J Switchenko, V Bachanova, JN Gerson, SK Barta, MJ Gordon, AV Danilov, NS Grover, S Mathews, M Burkart, R Karmali, Y Sawalha, BT Hill, N Ghosh, SI Park, DA Bond, M Hamadani, TS Fenske, P Martin, MK Malecek, BS Kahl, CR Flowers, BK Link, LD Kaplan, DJ Inwards, AL Feldman, ED Hsi, K Maddocks, KA Blum, NL Bartlett, JR Cerhan, JP Leonard, TM Habermann, MJ Maurer, JB Cohen	13/06/2023
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. Cancers	W Hanel, P Shindiapina, DA Bond, Y Sawalha, N Epperla, T Voorhees, RL Welkie, Y Huang, GK Behbehani, X Zhang, E McLaughlin, WK Chan, JE Brammer, S Jaglowski, JC Reneau, BA Christian, BM William, JB Cohen, RA Baiocchi, K Maddocks, KA Blum, L Alinari	24/02/2023
Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology	AS LaCasce, T Dockter, AS Ruppert, L Kostakoglu, H Schöder, E Hsi, J Bogart, B Cheson, N Wagner-Johnston, J Abramson, K Blum, JP Leonard, NL Bartlett	10/02/2023
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SC Rutherford, J Yin, L Pederson, G Perez Burbano, B LaPlant, M Shadman, H Li, ML LeBlanc, VP Kenkre, F Hong, KA Blum, T Dockter, P Martin, SH Jung, B Grant, C Rosenbaum, C Ujjani, PM Barr, JM Unger, BD Cheson, NL Bartlett, B Kahl, JW Friedberg, SJ Mandrekar, JP Leonard	10/01/2023
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies. Cancer research communications	A Chang, A Akhtar, L Lai, VM Orellana-Noia, SL Linderman, AA McCook-Veal, JM Switchenko, M Saini, RM Valanparambil, KA Blum, PB Allen, MJ Lechowicz, JT Romancik, A Ayers, A Leal, CB O'Leary, MC Churnetski, K Baird, M Kives, J Wrammert, AK Nooka, JL Koff, MV Dhodapkar, MS Suthar, JB Cohen, R Ahmed	01/12/2022
Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials. Clinical lymphoma, myeloma & leukemia	JG Dixon, Ç Çağlayan, D Chihara, T Nielsen, N Dimier, J Zheng, AK Wall, G Salles, F Morschhauser, R Marcus, M Herold, E Kimby, KA Blum, M Ghielmini, Q Shi, CR Flowers	01/11/2022
CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Clinical lymphoma, myeloma & leukemia	A Chang, L Lai, A Akhtar, S Linderman, V Orellana-Noia, M Saini, R Valanparambil, K Blum, P Allen, M Lechowicz, J Romancik, A Ayers, C O'Leary, M Churnetski, M Kives, A Nooka, J Koff, M Dhodapkar, M Suthar, J Cohen, R Ahmed	27/09/2022
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	A Chang, A Akhtar, SL Linderman, L Lai, VM Orellana-Noia, R Valanparambil, H Ahmed, VI Zarnitsyna, AA McCook-Veal, JM Switchenko, JL Koff, KA Blum, AA Ayers, CB O'Leary, MC Churnetski, S Sulaiman, M Kives, P Sheng, CW Davis, AK Nooka, R Antia, MV Dhodapkar, MS Suthar, JB Cohen, R Ahmed	10/09/2022
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma. Cancer research communications	KA Blum, JG Supko, MB Maris, IW Flinn, A Goy, A Younes, S Bobba, AM Senderowicz, S Efuni, R Rippley, G Colak, P Trojer, JS Abramson	01/08/2022
A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies. American journal of clinical oncology	PM Fracasso, SA Goodner, JD Wildi, MJ Naughton, GP Linette, R Govindan, BR Tan, KA Blum, GJ Jones, TE Pearce, DJ Levitt, GH Clamon	01/07/2022
End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma. British journal of haematology	JG Dixon, N Dimier, T Nielsen, J Zheng, R Marcus, F Morschhauser, AM Evens, M Federico, KA Blum, Q Shi	01/07/2022
A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Leukemia & lymphoma	DA Bond, Y Huang, BA Christian, S Jaglowski, D Benson, L Alinari, RA Baiocchi, JB Cohen, KA Blum, KJ Maddocks	01/07/2022
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. Blood advances	RA Harkins, SP Patel, MJ Lee, JM Switchenko, SM Ansell, NL Bartlett, KA Blum, AF Cashen, C Casulo, JW Friedberg, PB Johnston, BS Kahl, JP Leonard, BK Link, IS Lossos, P Martin, MJ Maurer, N Mehta-Shah, PM Reagan, JR Westin, JL Koff, CR Flowers	10/05/2022
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood advances	DA Bond, JM Switchenko, D Villa, K Maddocks, M Churnetski, AS Gerrie, S Goyal, K Shanmugasundaram, O Calzada, B Kolla, V Bachanova, JN Gerson, SK Barta, BT Hill, Y Sawalha, P Martin, E Maldonado, M Gordon, AV Danilov, NS Grover, S Mathews, M Burkart, R Karmali, N Ghosh, SI Park, N Epperla, T Badar, J Guo, M Hamadani, TS Fenske, MK Malecek, BS Kahl, CR Flowers, KA Blum, JB Cohen	14/12/2021
Controversies in the management of early-stage Hodgkin lymphoma. Hematology. American Society of Hematology. Education Program	KA Blum	10/12/2021
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. American journal of hematology	R Karmali, JM Switchenko, S Goyal, K Shanmugasundaram, MC Churnetski, B Kolla, V Bachanova, JN Gerson, SK Barta, MJ Gordon, AV Danilov, NS Grover, N Epperla, S Mathews, M Burkart, Y Sawalha, BT Hill, N Ghosh, SI Park, DA Bond, KJ Maddocks, T Badar, TS Fenske, M Hamadani, J Guo, M Malecek, BS Kahl, P Martin, KA Blum, CR Flowers, JB Cohen	01/11/2021
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. European journal of haematology	K Shanmugasundaram, S Goyal, J Switchenko, O Calzada, MC Churnetski, B Kolla, V Bachanova, JN Gerson, SK Barta, MJ Gordon, AV Danilov, NS Grover, S Mathews, M Burkart, R Karmali, Y Sawalha, BT Hill, N Ghosh, SI Park, N Epperla, DA Bond, T Badar, KA Blum, M Hamadani, TS Fenske, M Malecek, BS Kahl, P Martin, J Guo, CR Flowers, JB Cohen	01/09/2021
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood advances	JP Alderuccio, AJ Olszewski, AM Evens, GP Collins, AV Danilov, M Bower, D Jagadeesh, C Zhu, A Sperling, SH Kim, R Vaca, C Wei, S Sundaram, N Reddy, A Dalla Pria, C D'Angelo, U Farooq, DA Bond, S Berg, MC Churnetski, A Godara, N Khan, YK Choi, S Kassam, M Yazdy, E Rabinovich, FA Post, G Varma, R Karmali, M Burkart, P Martin, A Ren, A Chauhan, C Diefenbach, A Straker-Edwards, A Klein, KA Blum, KM Boughan, A Mian, BM Haverkos, VM Orellana-Noia, VP Kenkre, A Zayac, SM Maliske, N Epperla, P Caimi, SE Smith, M Kamdar, P Venugopal, TA Feldman, D Rector, SD Smith, A Stadnik, CA Portell, Y Lin, S Naik, S Montoto, IS Lossos, K Cwynarski	27/07/2021
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica	AS Zayac, AM Evens, A Danilov, SD Smith, D Jagadeesh, LA Leslie, C Wei, SH Kim, S Naik, S Sundaram, N Reddy, U Farooq, VP Kenkre, N Epperla, KA Blum, N Khan, D Singh, JP Alderuccio, A Godara, MS Yazdy, C Diefenbach, E Rabinovich, G Varma, R Karmali, Y Shao, A Trabolsi, M Burkart, P Martin, S Stettner, A Chauhan, YK Choi, A Straker-Edwards, A Klein, MC Churnetski, KM Boughan, S Berg, BM Haverkos, VM Orellana-Noia, C D'Angelo, DA Bond, SM Maliske, R Vaca, G Magarelli, A Sperling, MJ Gordon, KA David, M Savani, P Caimi, M Kamdar, MA Lunning, N Palmisiano, P Venugopal, CA Portell, V Bachanova, T Phillips, IS Lossos, AJ Olszewski	01/07/2021
Burkitt Lymphoma International Prognostic Index. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	AJ Olszewski, LH Jakobsen, GP Collins, K Cwynarski, V Bachanova, KA Blum, KM Boughan, M Bower, A Dalla Pria, A Danilov, KA David, C Diefenbach, F Ellin, N Epperla, U Farooq, TA Feldman, AS Gerrie, D Jagadeesh, M Kamdar, R Karmali, S Kassam, VP Kenkre, N Khan, SH Kim, AK Klein, IS Lossos, MA Lunning, P Martin, N Martinez-Calle, S Montoto, S Naik, N Palmisiano, D Peace, EH Phillips, TJ Phillips, CA Portell, N Reddy, A Santarsieri, M Sarraf Yazdy, KB Smeland, SE Smith, SD Smith, S Sundaram, AS Zayac, XY Zhang, C Zhu, CY Cheah, TC El-Galaly, AM Evens	01/04/2021
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood	AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, D Rector, S Sundaram, N Reddy, Y Lin, U Farooq, C D'Angelo, DA Bond, S Berg, MC Churnetski, A Godara, N Khan, YK Choi, M Yazdy, E Rabinovich, G Varma, R Karmali, A Mian, M Savani, M Burkart, P Martin, A Ren, A Chauhan, C Diefenbach, A Straker-Edwards, AK Klein, KA Blum, KM Boughan, SE Smith, BM Haverkos, VM Orellana-Noia, VP Kenkre, A Zayac, J Ramdial, SM Maliske, N Epperla, P Venugopal, TA Feldman, SD Smith, A Stadnik, KA David, S Naik, IS Lossos, MA Lunning, P Caimi, M Kamdar, N Palmisiano, V Bachanova, CA Portell, T Phillips, AJ Olszewski, JP Alderuccio	21/01/2021
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clinical cancer research : an official journal of the American Association for Cancer Research	JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, K Blum, JP Sharman, W Wierda, W Zhao, NA Heerema, Y Luan, EA Liu, JP Dean, S O'Brien	01/08/2020
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. American journal of hematology	LD Kaplan, MJ Maurer, W Stock, NL Bartlett, N Fulton, A Pettinger, JC Byrd, KA Blum, AS LaCasce, ED Hsi, YT Liu, DW Scott, D Hurd, AS Ruppert, F Hernandez-Ilizaliturri, JP Leonard, BD Cheson	01/06/2020
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. The Lancet. Haematology	G Thanarajasingam, JP Leonard, TE Witzig, TM Habermann, KA Blum, NL Bartlett, CR Flowers, BN Pitcher, SH Jung, PJ Atherton, A Tan, PJ Novotny, AC Dueck	01/06/2020
Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. Cancer	JB Cohen, L Wei, KJ Maddocks, B Christian, LT Heffner, AA Langston, MJ Lechowicz, P Porcu, CR Flowers, SM Devine, KA Blum	15/03/2020
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). Cancer	KA Blum, MY Polley, SH Jung, TJ Dockter, S Anderson, ED Hsi, N Wagner-Johnston, B Christian, J Atkins, BD Cheson, JP Leonard, NL Bartlett	01/10/2019
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	NL Bartlett, WH Wilson, SH Jung, ED Hsi, MJ Maurer, LD Pederson, MC Polley, BN Pitcher, BD Cheson, BS Kahl, JW Friedberg, LM Staudt, ND Wagner-Johnston, KA Blum, JS Abramson, NM Reddy, JN Winter, JE Chang, AK Gopal, A Chadburn, S Mathew, RI Fisher, KL Richards, H Schöder, AD Zelenetz, JP Leonard	20/07/2019
Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. British journal of clinical pharmacology	JH Hughes, MA Phelps, RN Upton, SE Reuter, Y Gao, JC Byrd, MR Grever, CC Hofmeister, G Marcucci, W Blum, KA Blum, DJR Foster	01/05/2019
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood	P Martin, NL Bartlett, KA Blum, S Park, K Maddocks, J Ruan, L Ridling, C Dittus, Z Chen, X Huang, G Inghirami, M DiLiberto, S Chen-Kiang, JP Leonard	14/03/2019
Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma. Clinical lymphoma, myeloma & leukemia	DA Bond, E Dotson, FT Awan, RA Baiocchi, KA Blum, K Maddocks	01/03/2019
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. Cancer medicine	F Lansigan, I Barak, B Pitcher, SH Jung, BD Cheson, M Czuczman, P Martin, E Hsi, H Schöder, S Smith, NL Bartlett, JP Leonard, KA Blum	01/01/2019
Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Leukemia & lymphoma	O Calzada, JM Switchenko, JJ Maly, KA Blum, N Grover, S Mathews, SI Park, M Gordon, A Danilov, N Epperla, TS Fenske, M Hamadani, CR Flowers, JB Cohen	01/12/2018
Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States. British journal of haematology	KA Blum, FG Keller, S Castellino, A Phan, CR Flowers	01/11/2018
Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer	IB Greenwell, AD Staton, MJ Lee, JM Switchenko, DF Saxe, JJ Maly, KA Blum, NS Grover, SP Mathews, MJ Gordon, AV Danilov, N Epperla, TS Fenske, M Hamadani, SI Park, CR Flowers, JB Cohen	01/06/2018
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA oncology	SM O'Brien, S Jaglowski, JC Byrd, R Bannerji, KA Blum, CP Fox, RR Furman, P Hillmen, TJ Kipps, M Montillo, J Sharman, S Suzuki, DF James, AD Chu, SE Coutre	01/05/2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood	S O'Brien, RR Furman, S Coutre, IW Flinn, JA Burger, K Blum, J Sharman, W Wierda, J Jones, W Zhao, NA Heerema, AJ Johnson, Y Luan, DF James, AD Chu, JC Byrd	26/04/2018
Treatment-Resistant Hodgkin Lymphoma: Defining the Role of Autologous Transplantation. Cancer journal (Sudbury, Mass.)	KA Blum	01/01/2018
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood advances	M Pilichowska, S Pittaluga, JA Ferry, J Hemminger, H Chang, JA Kanakry, LH Sehn, T Feldman, JS Abramson, A Kritharis, FJ Hernandez-Ilizaliturri, IS Lossos, OW Press, TS Fenske, JW Friedberg, JM Vose, KA Blum, D Jagadeesh, B Woda, GK Gupta, RD Gascoyne, ES Jaffe, AM Evens	12/12/2017

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	23/04/2024	Excellent care and helping us understand.
One star One star One star One star One star	03/03/2024	Dr Blum is great. She is so patient and knowledgeable
One star One star One star One star One star	14/01/2024	Dr. Blum is excellent. She reviewed my case and checked me well. She monitors my blood tests and helps chart my future with my lymphoma. He care is the best.
One star One star One star One star One star	12/01/2024	Dr. Blum has been a superior physician throughout my five-year cancer journey. Professional, respectful, brilliant, responsive, and caring during one of the most difficult times of my life.
One star One star One star One star One star	07/01/2024	I appreciate the care I received at this facility.
One star One star One star One star One star	26/12/2023	Excellent
One star One star One star One star One star	31/10/2023	Very informative, kind, and caring. Dr. Blum was knowledgeable and patient with all our questions.
One star One star One star One star One star	12/09/2023	Dr. Blum was patient, informative and caring. Meant a lot.
One star One star One star One star One star	15/08/2023	Dr. Blum was wonderful. She was clear, and knew my history - she wasn't trying to figure it out during my visit. She had some questions about my prior care that showed she knew my case.
One star One star One star One star One star	05/07/2023	Dr. Blum was thorough about her examination and follow up CT scans and lab work. Dr Blum makes me feel very comfortable about discussing my diagnosis and is very optimistic and positive.
One star One star One star One star One star	23/05/2023	Dr Kristie Bloom is AWESOME!
One star One star One star One star One star	12/03/2023	Dr. Blum and her staff were very patient,understanding,caring,and informative.
One star One star One star One star One star	26/02/2023	Dr Blum continues to provide all the information we need, answers all of our questions, and explains things in a way that is so easy to understand
One star One star One star One star One star	13/01/2023	Dr. Blum is outstanding
One star One star One star One star One star	28/08/2022	Dr Blum has been absolutely fantastic during my entire cancer experience. I have recommended her and the Winship clinic to several friends and plan to continue to do so
One star One star One star One star One star	08/07/2022	I am so happy to have found MY primary care physician on this first visit. And I am thankful for her understanding and organized style to getting me on a solid foundation with regard to my physical health (which will also strengthen my mental wellness)!